CD30+ Neoplasms of the Skin

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

DOI: 10.1007/s11899-011-0096-8

Cite this article as:
Duvic, M. Curr Hematol Malig Rep (2011) 6: 245. doi:10.1007/s11899-011-0096-8


Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma. After MF/SS, the next most common CTCLs are CD30+ lymphoproliferative disorders: self-regressing lymphomatoid papulosis (LyP) or tumors of anaplastic large-cell lymphoma (ALCL), which express high levels of tumor necrosis factor death receptor member 8, also called CD30. Although MF is not considered to be a CD30+ lymphoproliferative disorder, MF may co-exist with LyP lesions, and MF may express CD30, especially in the setting of large-cell transformation. The development of targeted therapy for CD30+ CTCLs will help in understanding the importance of the CD30 death receptor in pathogenesis and will improve treatment options.


Cutaneous T-cell lymphoma Lymphomatoid papulosis LyP Anaplastic large T-cell lymphoma ALCL Mycosis fungoides Ki-1 Hodgkin’s lymphoma Tumor necrosis factor member 8 CD30 Lymphoma Interferon regulatory factor 4 Large-cell transformation Anaplastic lymphoma kinase 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Texas, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations